

**Table 1. Patients' Characteristics**

	ICANS (n = 18)	non-ICANS (n = 6)	p-value
<b>Age at CAR-T infusion in years</b>			0.102
Median (range)	65 (42-73)	58 (42-71)	
<b>SEX</b>			0.586
Male	14	4	
Female	4	2	
<b>Diagnosis</b>			0.528
Diffuse large B-cell lymphoma	13	6	
High grade B-cell lymphoma	3	0	
Follicular lymphoma	2	0	
<b>Disease status at CAR-T infusion</b>			0.772
CR	4	1	
nonCR	14	5	
<b>Cellular infused product</b>			0.146
Tisa-cel	5	4	
Liso-cel	7	2	
Axi-cel	6	0	
<b>CRS grade</b>			0.092
No CRS	2	0	
Grade1	6	6	
Grade2	7	0	
Grade3	2	0	
Grade4	1	0	
<b>ICANS grade</b>			NA
Grade1	10	-	
Grade2	6	-	
Grade3	2	-	
Grade4	0	-	
<b>Day of symptom onset</b>			0.487
Median (range)	6 (3-38)	10 (1-21)	

ICANS immune effector cell-associated neurotoxicity syndrome, CAR chimera antigen receptor, CR complete remission, Tisa-cel tisagenlecleuce, Liso-cel lisocabtagene maraleuce, Axi-cel axicabtagene ciloleucel, CRS cytokine release syndrome